{"id":"NCT02667236","sponsor":"Aclaris Therapeutics, Inc.","briefTitle":"A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.","officialTitle":"A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01","primaryCompletion":"2016-10","completion":"2016-10","firstPosted":"2016-01-28","resultsPosted":"2017-11-13","lastUpdate":"2018-02-06"},"enrollment":450,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Seborrheic Keratosis"],"interventions":[{"type":"DRUG","name":"A-101 Solution","otherNames":[]},{"type":"OTHER","name":"Vehicle Solution","otherNames":[]}],"arms":[{"label":"A-101 Solution","type":"ACTIVE_COMPARATOR"},{"label":"Vehicle Solution","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, vehicle-controlled, parallel group study of A-101 Solution 40% compared with Vehicle Solution.","primaryOutcome":{"measure":"Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment","timeFrame":"Day 106 of the study","effectByArm":[{"arm":"A-101 Solution","deltaMin":9,"sd":null},{"arm":"Vehicle Solution","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["30365590"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":223},"commonTop":["Nasopharyngitis","Bronchitis","Upper Respiratory Infection","Seasonal Allergy","Actinic Keratosis"]}}